The uses described in the publications have not been authorized or approved by FDA.
Preclinical Product Development
https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2
Animal Challenge Studies – Hamsters
https://www.researchsquare.com/article/rs-76768/v1
Animal Challenge Studies – Rhesus Macaques
https://www.nature.com/articles/s41467-021-21639-w
Human Clinical Trials – Phase I
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext
Human Clinical Trials – Phase II
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2
https://ocugen.com/wp-content/uploads/2021/05/Inactivated-COVID-19-vaccine-BBV152COVAXIN-effectively-neutralizes-recently.pdf
COVAXIN effectively neutralizes B.1.617 variant of SARS-CoV-2
https://ocugen.com/wp-content/uploads/2021/04/BioRxIv-Neutralization-of-variant-under-investigaton-B.1.617-with-sera-of-BBV152-vaccinees.pdf
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
https://ocugen.com/wp-content/uploads/2021/05/Neutralization-of-B.1.1.28-P2-variant-with-sera-of-natural-SARS-CoV-2-infection-and.pdf
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1.full.pdf
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext
Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
https://www.medrxiv.org/content/10.1101/2021.11.14.21266294v1
